1.3114
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Appoints Robert E. Hoffman as New Director - TipRanks
Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire
Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan
Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com India
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan
BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener
Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire
Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com
FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan
Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa
Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com
Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India
Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Esperion stock hits 52-week low at $1.55 amid market challenges - Investing.com Australia
Esperion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Q3 Earnings Forecast for ESPR Issued By HC Wainwright - Defense World
Esperion Therapeutics, Inc. SEC 10-K Report - TradingView
Esperion Therapeutics Inc. (ESPR) reports earnings - Quartz
Brokers Set Expectations for ESPR Q1 Earnings - Defense World
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts - Defense World
Esperion stock target holds at $4 on JMP’s optimistic outlook By Investing.com - Investing.com South Africa
Esperion stock target holds at $4 on JMP’s optimistic outlook - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright - Defense World
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart
Esperion stock hits 52-week low at $1.58 amid challenges By Investing.com - Investing.com Australia
Esperion Therapeutics Reports Strong Revenue Growth in 2024 - TipRanks
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Esperion Therapeutics stock surges over 9% on strong Q4 results - Investing.com
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Esperion Therapeutics Q4 Loss Narrows - Nasdaq
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Esperion Therapeutics stock surges over 9% on strong Q4 results By Investing.com - Investing.com Canada
ESPERION THERAPEUTICS Earnings Results: $ESPR Reports Quarterly Earnings - Nasdaq
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):